¼º±Õ°üÀÇ´ë »ï¼º¼¿ïº´¿ø À̽Ŀܰú ±èÁ¾¸¸ ±³¼ö(»çÁø)°¡ Áö³ 10¿ù 31ÀϺÎÅÍ 11¿ù 1ÀϱîÁö ¼Ò°øµ¿ ·Ôµ¥È£ÅÚ¿¡¼ ¿¸° ´ëÇÑÀ̽ÄÇÐȸ Ãß°èÇмú´ëȸ¿Í Áö³´Þ 27ÀϺÎÅÍ 29ÀϱîÁö ¼¿ï Coex ÄÁº¥¼Ç¼¾ÅÍ¿¡¼ ¿¸° Çѱ¹°£´ãÃé¿Ü°úÇÐȸ Ãß°èÇмú´ëȸ¿¡¼ °¢°¢ ¿ì¼ö ¿¬Á¦»ó°ú Çмú»óÀ» ¼ö»óÇß´Ù.
±è ±³¼ö´Â ´ëÇÑÀ̽ÄÇÐȸ¿¡¼ ‘Çѱ¹¿¡¼ CÇü °£¿°À¸·Î °£ÀÌ½Ä È¯ÀÚÀÇ ´Ù±â°ü °á°ú(Factor related Outcomes in HCV patients after liver transplantation in Korea: Multicenter Study)’À¸·Î ¿ì¼ö ¿¬Á¦»ó, Çѱ¹°£´ãÃé¿ÜÇÐȸ Ãß°èÇмú´ëȸ¿¡¼± ‘ABO Ç÷¾×Çü ºÒÀÏÄ¡¿Í ABO Ç÷¾×Çü ÀÏÄ¡ »ýü ºÎºÐ °£À̽ÄÀÇ °á°ú ºñ±³ (Outcomes between ABO-incompatible LDLT and ABO-compatible LDLT: A Matched Study)’À̶õ ³í¹®À¸·Î Çмú»óÀ» °Å¸ÓÁá´Ù.
±è ±³¼ö´Â Àå±âÀ̽ļ¾ÅÍ ±³¼öÆÀ°ú Áö³ 6¿ù12ÀÏ¿¡ »ýü°£ÀÌ½Ä 1,160°Ç°ú ³ú»çÀÚ °£ÀÌ½Ä 340°Ç µî ÃÑ 1,500°ÇÀÇ °£ À̽ļö¼úÀ» ´Þ¼ºÇÑ ¹Ù ÀÖ´Ù.
ÃÖ±Ù 10¿ù13ÀÏ¿£ À̼®±¸·±ÇÁØÇõ ±³¼öÆÀ°ú ±¹³» ÃÖÃÊ·Î °£ ±â´É º¸Á¶ ½Ã½ºÅÛ ‘¹ÙÀÌ¿À Àΰø °£’À» ÀÌ¿ëÇØ ±Þ¼º °£ºÎÀü ȯÀÚ Ä¡·á¿¡ ¼º°øÇß´Ù.